Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276426 | 0.84 | AURKA (0.37) | HTR2CADORA2AL3MBTL1ADORA1 | |
| SCHEMBL5474686 | 0.74 | AURKA (0.50) | LMNA | |
| SCHEMBL5477688 | 0.69 | NUDT1 (0.55) | HTR2CADORA2AL3MBTL1NUDT1DYRK1A | |
| SCHEMBL15956956 | 0.69 | AURKA (0.50) | HTR2C | |
| SCHEMBL6527273 | 0.69 | HTR2C (0.42) | HTR2CADORA2AL3MBTL1NUDT1DYRK1A | |
| SCHEMBL103894 | 0.68 | HTR2C (0.53) | HTR2CADORA2AL3MBTL1NUDT1ADORA1 | |
| SCHEMBL5486787 | 0.67 | EPHB4 (0.45) | HTR2CADORA2AL3MBTL1DYRK1A | |
| SCHEMBL5489000 | 0.66 | EPHB4 (0.53) | — | |
| SCHEMBL5481710 | 0.66 | HTR2C (0.48) | HTR2CADORA2AL3MBTL1NUDT1DYRK1A | |
| SCHEMBL24386932 | 0.65 | HTR2C (0.50) | HTR2CL3MBTL1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259164-B2 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | CGI PHARMACEUTICALS, INC. (US) | 2007-08-21 | — | — | US | disclosed |
| WO-2005019220-A9 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY | CELLULAR GENOMICS INC (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050085484-A1 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | GILEAD CONNECTICUT, INC. | 2005-04-21 | — | — | US | disclosed |
| WO-2005019220-A2 | SUBSTITUTED IMIDAZO[1,2-A]PYRAZINES AS MODULATORS OF KINASE ACTIVITY | CELLULAR GENOMICS INC. (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085484-A1 | Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity | ERBB4, MAP4K4, EPHB4 | HTR2C 2114/4885ADORA2A 1221/4885L3MBTL1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.